Pathogenica Signs Agreement with Illumina

                  Pathogenica Signs Agreement with Illumina

Companies to co-market Pathogenica HAI kit for MiSeq in Asia Pacific

PR Newswire

BOSTON, July 17, 2013

BOSTON, July 17, 2013 /PRNewswire/ --Pathogenica Inc. announced today it had
entered into an agreement with Illumina, whereby the parties will co-market in
the Asia Pacific region a new version of Pathogenica's HAI BioDetection kit
compatible with Illumina's MiSeq benchtop sequencing system. The combined
solution will enable users to identify an expanded panel of bacteria and drug
resistance genes present within clinical specimens and mixed cultures or

The new version of the HAI BioDetection kit, currently under development, will
be a research use only test that enables identification and sub-typing of
bacterial species responsible for over 95 percent of hospital acquired
infections. The solution provides sequence-level resolution with automated
analysis software in a multiplexed assay that makes hospital-wide surveillance
practical. Species identified by the new kit will include (but not be limited
to): A. baumannii, C. difficile, E. coli, K. pneumonia, P. aeruginosa, and S.

"We are excited to partner with Illumina to bring next-generation
sequencing-based surveillance to labs in Asia," said Yemi Adesokan, CEO of
Pathogenica. "The introduction of an Illumina-compatible version of our kit
emphasizes the platform-agnostic flexibility of our technology, and allows us
to reach new users in the large number of clinical-facing facilities keen to
use Illumina's sequencing technology."

Pathogenica's BioDetection solution has the capability to bypass the
requirement of bacterial isolation and culture, drastically expediting
workflow, and can process 24-48 samples simultaneously per sequencing run.

Products referenced are for research use only. Not intended for diagnostic

About Pathogenica

Pathogenica ( is combining the power of Cloud-based DNA
sequencing analysis and next-generation DNA sequencing to revolutionize
pathogen identification and enable real-time bio-surveillance. Its DxSeq™
platform offers new applications in health services through rapid multiplex
identification of pathogens and drug resistance genes, providing personalized
diagnosis for infectious diseases and enabling more effective patient care.

Media Contact:

Yemi Adesokan


This press release was issued through eReleases® Press Release Distribution.
For more information, visit

SOURCE Pathogenica Inc.

Press spacebar to pause and continue. Press esc to stop.